Skip to main content
. 2010 Feb 16;102(5):883–891. doi: 10.1038/sj.bjc.6605570

Figure 5.

Figure 5

In situ hybridisation of miR-145 and immunohistochemistry examination of FSCN1 in clinical BC specimens: (A) H&E staining, tumour, and surrounding smooth muscle; (B) immunohistochemical staining of FSCN1 showing strong expression in tumour lesion; (C) in situ hybridisation of miR-145 showing faint expression in tumour lesion and strong expression in smooth muscle layer; (D) no staining by scramble-control probe; and (E) FSCN1 protein expression in invasive and non-invasive BC specimens. Low-grade bladder cancer without invasion (pTa) (upper panel, original magnification × 400). High-grade bladder cancer with involvement of the muscularis (pT2) (lower panel, original magnification × 400).